



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 23, 2023 January 24, 2024

Prevymis® (letermovir)

LENGTH OF AUTHORIZATION: Hematopoietic stem cell transplant - Up to 100 days post-transplantation
Kidney transplant - Up to 200 days post-transplantation

REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Medication must be prescribed for one of the following:
 - Prophylaxis of cytomegalovirus (CMV) infection and disease in a CMV-seropositive recipient (R+) of an allogeneic hematopoietic stem cell transplant (HSCT). *Clinical documentation (i.e., progress notes, labs, discharge summary, etc.) must be provided; OR*
 - Prophylaxis of CMV disease in a kidney transplant recipient at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]). *Clinical documentation (i.e., progress notes, labs, discharge summary, etc.) must be provided.*
- One of the following must be true based on the indication:
 - CMV prophylaxis following hematopoietic stem cell transplant: Medication is being initiated no more than 28 days post-transplant; **OR**
 - CMV prophylaxis following kidney transplant: Medication is being initiated no more than 7 days post-transplant.
- For the injectable formulation, clinical justification explaining why the patient is not a candidate for oral therapy must be provided.
- Medication will not be taken concurrently with any of the following:
 - Pimozide
 - Ergot Alkaloids (i.e., Cafergot, Migranal®, Trudhesa™, etc.)
 - Pitavastatin (Livalo® or Zypitamag®) and simvastatin when co-administered with cyclosporine.
- Treatment is being prescribed by, or in consultation with a provider who specializes in infectious disease, hematology, or organ transplantation.

Note: Prevymis® is indicated for CMV prophylaxis in patients at high risk for CMV reactivation following an allogeneic HSCT or kidney transplant, and not for the treatment of an active CMV infection.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as:
 - Tablet - 240 mg and 480 mg
 - Injection - 240 mg/12 mL (20 mg/mL) and 480 mg/24 mL (20 mg/mL) single-dose vials